硫普罗宁治疗重度非酒精性脂肪性肝病的疗效观察

摘要

Objective To observe the clinical efficacy of Tiopronin in treatment of non-alcoholic fatty liver disease (NAFLD). Methods Thirty patients with severe non-alcoholic fatty liver disease and 30 healthy controls were recruited. Those patients with severe NAFLD were treated with Tiopronin for 3 months. BMI, endotoxin, leptin, IL-6, ALT and IL-8 levels were measured before and after treatment. Results Compared with healthy controls, endotoxin, leptin,ALT, IL-6 and IL-8 levels were increased significantly ( P ＜ 0.05 ). Compared with the NAFLD patients before treatment, endotoxin, leptin, IL-6 and IL-8 levels were decreased after teratment ( P ＜ 0.05 ). There were significant difference in endotoxin, leptin, IL-6 and IL-8 levels between the therapy group and the control group. Conclusion Nonalcoholic fatty liver disease accompanies intestinal endotoxemia. Leptin, IL-6 and IL-8 have played important roles in the pathogenesis and progression of non-alcoholic fatty liver disease. Tiopronin could decrease the levels of the endotoxin,leptin, IL-6 and IL-8. Tiopronin is safe in the treatment of non-alcoholic fatty liver disease.%目的 探讨硫普罗宁治疗重度非酒精性脂肪性肝病(NAFLD)的临床疗效.方法 选取重度非酒精性脂性肪肝病患者30例,测定患者及30例健康对照者的体质量指数、内毒素、瘦素、IL-6、IL-8水平.评价重度非酒精性脂肪性肝病患者采用硫普罗宁治疗3个月后,内毒素、瘦素、ALT、IL-6、IL-8的水平变化.结果 与对照组比较,非酒精性脂肪性肝病患者内毒素升高,伴随内毒素水平升高,瘦素、ALT、IL-6、IL-8在非酒精性脂肪性肝病患者中也明显升高(P＜0.05).硫普罗宁治疗后,患者上述指标明显下降.结论 NAFLD患者存在肠源性内毒素血症,瘦素、IL-6、IL-8等细胞因子在非酒精性脂肪性肝病发病中具有重要的致病作用,硫普罗宁可明显改善内毒素血症,通过降低瘦素、IL-6、IL-8等细胞因子,治疗非酒精性脂肪性肝病安全、有效.